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There is an ever-increasing body of literature examining gene–environment interactions in psychiatry, reﬂecting
a widespread belief that such studies will aid identiﬁcation of novel risk factors for disease, increase understanding
about underlying pathological mechanisms, and aid identiﬁcation of high-risk groups for targeted interventions. In
this article we discuss to what extent studies of gene–environment interactions are likely to lead to any such beneﬁts
in the future.
Received 9 June 2009 ; Revised 7 August 2009 ; Accepted 7 August 2009 ; First published online 24 September 2009
Key words : Additive, epidemiology, gene–environment interactions, genetics, multiplicative.
Introduction
The processes underlying most psychiatric disorders
are probably extremely complex. Studying how the
combined eﬀects of genes and environment impact
upon risk of disease seems an intuitively attractive
approach, and there is an ever-increasing body of
literature examining gene–environment interactions
(GrE) in psychiatry.
There are three main arguments put forward as
to why studies of GrE may be helpful : (1) they may
make it easier to identify novel genetic or environ-
mental risk factors for disease, (2) they may increase
our understanding about underlying pathological
mechanisms of disease, and (3) they may aid identiﬁ-
cation of high-risk groups that might beneﬁt from
targeted interventions. In this article we discuss
whether or not the study of GrE is likely to lead to any
of these potential beneﬁts. Although we focus mainly
on gene–environment interactions, the arguments we
present hold equally well for studies of gene–gene or
environment–environment interactions.
Measuring interaction
Within epidemiology, the term interaction is used to
describe the situation where the association between
one exposure (risk factor) and disease varies according
to the presence or absence of another exposure.
Where one exposure has an opposite eﬀect on
disease risk according to the presence or absence of
another exposure (a qualitative interaction), then the
discovery of such an interaction is important as this
can indeed lead to all of the potential advantages de-
scribed above. For example, it has been reported that,
in the presence of high paternal antisocial personality
(ASP) traits, the risk of child conduct problems in-
creases the more time the father lives with the child,
but with an opposite eﬀect if paternal ASP traits are
low, such that the risk of child conduct problems de-
creases the more time the father lives with the child
(Jaﬀee et al. 2003 ; Blazei et al. 2008). Findings such as
this can potentially have important implications for
ﬁnding risk factors, understanding aetiology and
identifying high-risk groups. However, such qualitat-
ive interactions have only rarely been observed in
medicine and are not the main focus of the discussions
that follow. Most interactions that have been described
in the psychiatric literature are less extreme ones, and
the potential advantages from identifying such quan-
titative rather than qualitative interactions are much
less clear.
To study how exposure to two risk factors in com-
bination aﬀects disease risk, we compare data to pre-
dictions from statistical models. Statistical interaction
occurs when the risk of disease if exposed to both
factors A and B is diﬀerent from that predicted by the
statistical model being used. These predictions are
usually modelled on either additive or multiplicative
scales, and it is important to appreciate that interac-
tions under these models mean diﬀerent things.
Statistical interaction is therefore model dependent
and, as demonstrated below, it is meaningless to speak
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of interactions without specifying the statistical model
to which they refer.
For example, in a study of risk diﬀerences or dif-
ferences between means, the model is on an additive
scale. The null hypothesis for statistical interaction in
this model is that the joint eﬀect of being exposed to
both A and B is additive (Table 1). Departure from this
(less than or greater than an additive eﬀect) will pro-
vide evidence of statistical interaction. A hypothetical
example of an additive relationship is given in Table 2.
However, if ratio measures (such as risk ratios or
odds ratios) are used to study the association between
exposures and disease, these are modelled on a multi-
plicative scale, for example using logistic regression.
The null hypothesis for statistical interaction in this
model is that the joint eﬀect of being exposed to both
A and B is multiplicative (Table 1). Departure from
this (super- or submultiplicativity) will provide evi-
dence of statistical interaction. A hypothetical example
of a multiplicative relationship is given in Table 3.
Note that the data in Table 2 show evidence of
statistical interaction if risk ratios are examined
(multiplicative model), although there is no statistical
interaction if risk diﬀerences are studied (additive
model). Table 3, however, shows no evidence of stat-
istical interaction if risk ratios are examined but shows
statistical interaction if risk diﬀerences are studied.
Statistical interaction is therefore both present and
absent in each of the two hypothetical examples given
in Tables 2 and 3, depending on whether the data
in each example are analysed under an additive or a
multiplicative model. With the exception of qualitative
interactions, statistical interaction is therefore model
dependent, and does not have any clear biological
meaning (Clayton & McKeigue, 2001). If a study is
adequately powered, evidence of statistical interaction
can always be found by looking at both risk diﬀer-
ences and risk ratios within the same data.
Is there a ‘correct ’ model to use?
Under the suﬃcient-component-cause model of dis-
ease it can be argued that risk factors co-participating
as causal components in any one causal model of
Table 1. Examples of statistical models used to study interactions
Statistical model Null hypothesis
Additivea Risk (A and B)=Risk (A only)+Risk (B only)xRisk
(neither A nor B)
Multiplicative Risk ratio (A and B)=Risk ratio (A only)rRisk ratio (B only)
a Although beyond the scope of this article, methods have been developed to
calculate a more valid measure of synergism (Darroch, 1997) that are also modelled
on an additive scale.
Table 2. Hypothetical 1-year cumulative incidence of
schizophrenia (per 10 000) given an additive relationship between
heavy cannabis use and COMT rs4680 valine allele on risk of
schizophrenia
Risk of schizophrenia
No cannabis Cannabis
Valine absent 1 10
Valine present 5 14
Risk diﬀerence (RD) for cannabis use is 9 where valine is
absent (10 – 1), and is also 9 where valine is present (14 – 5) ;
RDs equal no additive interaction. However, the risk ratio
(RR) for cannabis use is 10 where valine is absent (10/1)
but is 2.8 where valine is present (14/5) ; RRs unequal
multiplicative interaction. Note that where RDs for cannabis
are the same whether people have the valine allele or not,
the RRs will be diﬀerent.
Table 3. Hypothetical 1-year cumulative incidence of
schizophrenia (per 10 000) given a multiplicative relationship
between heavy cannabis use and COMT rs4680 valine allele
on risk of schizophrenia
Risk of schizophrenia
No cannabis Cannabis
Valine absent 1 10
Valine present 5 50
Risk diﬀerence (RD) for cannabis use is 9 where valine is
absent (10–1), but is 45 where valine is present (50–5) ; RDs
unequal additive interaction. However, the risk ratio (RR)
for cannabis use is 10 where valine is absent (10/1) and is also
10 where valine is present (50/5) ; RRs equalno multipli-
cative interaction. Note that where RRs for cannabis are the
same whether people have the valine allele or not, the RDs
will be diﬀerent.
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disease will show departure from additivity
(Greenland et al. 2008). This concept is sometimes re-
ferred to as ‘biological interaction ’ but we will avoid
using this term as it can be ambiguous, often being
misinterpreted as though it tells us something about
pathological mechanisms. It does not ; it tells us only
that both risk factors A and B played a causal role
in those particular cases of disease, and that some
individuals only experienced the disease because they
were exposed to both risk factors A and B (i.e. they
would not have developed the disease if either A or B
were absent) (Greenland et al. 2008). It is important to
understand that neither interaction under an additive
model nor under a multiplicative one is likely to tell us
anything about the underlying biology or pathology
beyond that from the study of main eﬀects only
(except perhaps where qualitative interactions occur)
(Thompson, 1991).
Consider an example (taken from Rothman &
Greenland, 2005) of an elderly person who falls and
fractures their hip, where other factors contributing
to the fall include disturbed balance resulting from a
childhood head injury, the icy weather, the type of
shoes they were wearing, their body weight, and the
strong wind at the time. If any of these component
causes had been absent, that person would not have
broken their hip, and there will be interaction on an
additive scale between all of these factors. Within
epidemiology, such non-additivity is perhaps what
we might expect for most risk factors acting on any
disease of complex multifactorial aetiology, where risk
factors are neither necessary nor suﬃcient to bring
about disease. As Greenland et al. (2008) note, we
would rarely expect to observe additivity between
risk factors as it is very unlikely that risk factors never
co-participate in any causal models of disease.
In the absence of any strong theoretical grounds
upon which to base our null hypothesis for interaction,
this expectation that most risk factors combine non-
additively seems a reasonable assumption to make.
Indeed, empirical evidence suggests that, where the
combined eﬀect of two risk factors on disease has been
examined, ﬁndings in general tend to support a
multiplicative (or at least greater than additive)
pattern of joint risk, both in other ﬁelds of medicine
(Godsland et al. 2000 ; Morgan et al. 2004; JBS,
2005 ; Wraith & Mengersen, 2007) and in psychiatry
(Cougnard et al. 2007 ; van Os et al. 2008 ; Clarke et al.
2009). We recently examined the patterns of schizo-
phrenia risk for pair-wise combinations of ﬁve risk
factors for schizophrenia (cannabis use, lower IQ
score, other psychiatric diagnoses, poor social adjust-
ment, and disturbed behaviour) in the 1969 Swedish
conscript cohort (personal communication). Of 10
possible combinations, we observed statistical evi-
dence of super-additivity in seven of these, with weak
evidence in two others.
These ﬁndings, in conjunction with observations
from other areas of medicine, suggest that multipli-
cative models may represent a better ﬁt than additive
models for data describing the combination of risk
factors on disease. However, irrespective of the choice
of the most appropriate model to use, perhaps the
important question that remains is : how useful is it to
study interactions?
Why study interactions?
Let us now consider the three main reasons put for-
ward as arguments as to why evidence of interaction
may be helpful.
First, study of interactions may allow us to ﬁnd
evidence of risk factors for disease that would not
be found if only main eﬀects of exposures were
examined. As an example, let us imagine that we want
to examine whether the valine (Val) allele of Val158Met
(rs4680) within the catechol-O-methyl transferase gene
(COMT) is a risk factor for psychosis, and that this
genetic eﬀect varies according to whether or not
someone uses cannabis.
Some of the hypothetical patterns of risk whereby
interactions may occur are depicted in Fig. 1. Note that
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Fig. 1. Hypothetical interactions between COMT rs4680 valine allele (V+ where valine allele present, Vx where absent)
and cannabis use (C+ where cannabis exposure present, Cx where absent) on risk of psychosis.
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in Fig. 1a, the Val allele is a risk factor for psychosis in
both cannabis users and non-users, although it is more
strongly associated in users. In this example, the av-
erage eﬀect in the whole population (regardless of
cannabis use status) will be that the Val allele increases
psychosis risk, and therefore the study of interactions
here will not greatly beneﬁt identiﬁcation of COMT
variation as a risk factor for psychosis. In Fig. 1b,
however, the average eﬀect of the Val allele on psy-
chosis risk in the population may be minimal if most
people in the population do not use cannabis. In this
case, stratiﬁcation of the eﬀect of COMT variation by
cannabis use may allow identiﬁcation of the Val allele
as a risk factor for psychosis in cannabis users. In
Fig. 1c (a qualitative, cross-over interaction), the aver-
age eﬀect of the Val allele on psychosis risk in the
population may be zero if there are equal numbers of
cannabis users and non-users in the population. In this
case, stratiﬁcation of the eﬀect of COMT variation
by cannabis use would allow identiﬁcation of the Val
allele as a risk factor for psychosis in cannabis users,
but a protective factor in non-users.
In the original report of this putative interaction
(Caspi et al. 2005), cannabis use was associated with
a 10-fold increase in risk of psychosis in Val homo-
zygotes, but with no increase in risk in those without
the valine allele (pattern similar to Fig. 1b). If such an
interaction eﬀect size was correct, however, then we
might expect main eﬀects to be observed for both ex-
posures without the need to study interactions given
the frequencies of the Val allele and of cannabis use in
the population.
Of the three patterns described above, Fig. 1a seems
the most plausible biologically, whereas Fig. 1c seems
the least plausible (though not impossible). Patterns of
interaction as seen in Fig. 1b can be seen in single gene
disorders (e.g. phenylketonuria), but it seems unlikely
such a pattern would be observed for epidemiological
studies of multifactorial complex diseases given that
risk factors are neither necessary nor suﬃcient to
cause disease. Given the rather extreme interactions
required therefore for studies of GrE to help identify
novel risk factors for disease [i.e. patterns similar to
Fig. 1(b or c)], it seems unlikely that studies of interac-
tions will contribute substantially to the identiﬁcation
of novel risk factors for disease (Munafo et al. 2009).
The second reason put forward for studying inter-
actions is that this may lead to an increased under-
standing of disease aetiology. However, as discussed
above, statistical interaction under an additive model
(and lack of statistical interaction under a multiplicat-
ive model is compatible with this) simply tells us
that both risk factors are component causes of a causal
model of disease, and nothing about pathological
mechanisms (Thompson, 1991 ; Greenland et al. 2008).
For example, if a greater than additive relationship
between stressful life events (SLEs) and variation
within the serotonin transporter locus (5-HTTLPR)
were found, it would be incorrect to interpret this as
evidence that SLEs increase depression risk through
eﬀects on the serotonergic system. In reality, this
might be true, and evidence for this could be obtained
from other studies, but it would be incorrect to deduce
this on the basis of an additive (or indeed a multi-
plicative) interaction between SLEs and 5-HTTLPR.
Studies of environment–environment interactions
(ErE) have been ongoing for decades within epi-
demiology, and as yet there has been little evidence
that studying interactions has beneﬁted understand-
ing of the pathogenesis of the diseases examined
(Clayton & McKeigue, 2001). It is possible that more
extreme interactions (e.g. super-multiplicative) may be
informative about disease aetiology, but in the main it
is probably only qualitative interactions that will in-
crease understanding of biological mechanisms be-
yond that gained from studying main eﬀects only
(Thompson, 1991). Such interactions are important to
ﬁnd, if present, although evidence to date suggests
they are very uncommon.
The third reason put forward for studying interac-
tions is that they may allow for speciﬁc targeting of
interventions in high-risk groups. Targeted interven-
tions are often an ineﬃcient approach at a population
level, given that most individuals who develop a dis-
ease are not usually in the targeted high-risk groups
(Rose, 2005), but such a strategy can be important at an
individual level.
In fact, where the relationship between two risk
factors is greater than additive, the largest reduction in
absolute risk of disease will always be obtained from
interventions targeted at those exposed to both factors.
Evidence of additive interaction would therefore sup-
port an approach of targeting high-risk groups, but
seems unnecessary given that, as discussed earlier, the
relationships between risk factors for multifactorial
complex diseases are unlikely to be truly additive at an
epidemiological level. Indeed, the programme of in-
terventions aimed at reducing cardiovascular disease
by speciﬁc targeting of high-risk groups is based upon
the assumption of multiplicative models of combined
eﬀects on risk (JBS, 2005). Where very strong interac-
tions occur (e.g. patterns similar to Fig. 1b), the case for
selective interventions may be strengthened, but it is
where qualitative interactions occur that clearly has
the most important implications for targeting high-
risk groups.
The practical implications, therefore, from studying
GrE are likely to be limited for epidemiological
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studies, although they might be greater for studies of
pharmacokinetics and more direct studies of cell or
system biology.
Costs of studying interactions
The possible advantages of studying interactions have
to be weighed up against the potential costs. The main
problem of studying interactions is that of multiple
testing (Colhoun et al. 2003; Hunter, 2005 ; Sullivan,
2007 ; Flint & Munafo, 2008), particularly now with the
availability of vast arrays of genotypes from genome-
wide studies that can potentially be used in studies of
GrE. Even where studies aim to replicate tentative
interactions reported, multiple testing is a common
problem as tests are often carried out under diﬀerent
genetic models, using multiple measures of environ-
mental exposures, using multiple outcomes, or exam-
ining subgroups. This problem could be reduced if :
(a) all interactions reported were treated as highly
tentative and most likely to be due to chance (regard-
less of strength of statistical evidence or biological
plausibility) ; (b) strict criteria for claiming replication
were observed, with use of the same statistical and
genetic models, the same (or very similar) environ-
mental measure, and the same outcome, without
addition of further (e.g. three-way or four-way) inter-
actions (i.e. avoiding further subgroup analyses) ; and
(c) all interaction tests performed were reported and
published to reduce publication bias.
Studies of GrE in psychiatry frequently violate
these criteria. Perhaps this is best exempliﬁed by
claims of replicated evidence of an interaction be-
tween 5-HTT and SLE on risk of depression (Moﬃtt
et al. 2005 ; Rutter et al. 2006 ; Uher & McGuﬃn, 2008).
Most of the apparent replication studies use diﬀerent
statistical models, only report ﬁndings in subgroup
analyses, or report qualitatively diﬀerent patterns of
interaction to the original ﬁndings (Zammit & Owen,
2006; Munafo et al. 2009 ; Risch et al. 2009).
Problems of studying interactions also include
lower statistical power (Munafo et al. 2009) and re-
duced precision compared to study of main eﬀects,
and problems related to misclassiﬁcation of exposures
and confounders that are more complex than those for
the study of main eﬀects (Greenland, 1993).
Lack of appreciation of the diﬀerent interpretation
of interaction results under diﬀerent statistical models
and the erroneous assumption that evidence of inter-
actions tells us anything about underlying pathologi-
cal mechanisms have led to much misunderstanding
of how ﬁndings in this ﬁeld should be interpreted.
Any gains from studying interactions are therefore not
only likely to be somewhat limited but also to come at
a cost ; studying interactions in the context of the
common errors and misunderstanding highlighted
above wastes valuable (and limited) time and re-
sources. Problems of poor methodology and incorrect
interpretation of results are of course common to all
areas of research. However, these are likely to be more
common in the study of interactions because of the
increased complexity involved. Furthermore, and of
greater concern, is that this lack of understanding
means that reports of putative interactions have the
potential to start impacting, inappropriately, upon
clinical practice (Wilhelm et al. 2009).
Conclusions
Although providing evidence of interaction without
specifying the underlying model is clearly meaning-
less, the choice of which is the most appropriate model
to use is less clear. Empirical evidence supports the
view that it seems unlikely that risk factors for multi-
factorial complex diseases will combine additively and
not ever co-participate in any causal models of disease.
Given this, it follows that subjects with co-exposure to
risk factors will beneﬁt the most from targeted inter-
ventions, and studies of interactions will rarely add
anything of value to such an approach. Furthermore,
irrespective of the model used, it is unlikely that
evidence of interaction will increase understanding of
pathogenesis, often advocated as one of the beneﬁts
potentially arising from studying interactions. The
only exception is where qualitative interactions occur,
and such interactions have only rarely been described
in epidemiology. Other putative beneﬁts, such as in-
creased power to detect novel risk factors, are also
likely to occur only in uncommon circumstances, and
any potential gains need to be balanced against the
substantial problems such as multiple testing and
publication bias inherent in such studies.
There has been a recent increase in the development
of research projects around GrE and funding of re-
search in this area. Gains from such studies will only
accrue if studies are set within a clear understanding
of what is being studied, and where results from stat-
istical interactions examined are interpreted appro-
priately.
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